CEACAM5 and metastatic colorectal cancer: In the group of 64 patients with recurrent or metastatic colorectal cancer, they nonrandomly compared 125I-B72.3 monoclonal antibody in 30 patients to 125I-F023C5 monoclonal antibody fragment that reacts with CEA in 34 patients [304].